



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

Re: PRELAY/REZULIN<sup>®</sup>  
Docket No. 97E-0145

APR 16 1998

Stephen G. Kunin  
Deputy Assistant Commissioner for  
Patent Policy and Projects  
Office of the Assistant Commissioner for Patents  
U.S. Patent and Trademark Office  
Crystal Park Building 2, Suite 919  
Washington, DC 20231

Dear Mr. Kunin:

This is in regard to the patent term extension application for U.S. Patent No. 4,572,912 filed by Sankyo Co., Ltd. under 35 U.S.C. § 156. The patent claims the human drug product PRELAY/REZULIN<sup>®</sup> (troglitazone), New Drug Application NDA 20-719.

In the September 3, 1997, issue of the Federal Register (62 Fed. Reg. 46501), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before March 2, 1998, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Herbert Goodman, Esq.  
Fritzhauf, Holtz, Goodman, Langer & Chick, P.C.  
767 Third Ave., 25th Floor  
New York, NY 10017-2023